Patients with neuromyelitis optica spectrum disorder (NMOSD) may be prone to experiencing worse COVID-19 outcomes. As an autoimmune disease, NMOSD is detrimental to the optic nerve and central nervous system. Patients with NMOSD may experience disease onset at a later age, have comorbidities, and often be treated with immunosuppressive therapy, such as rituximab, azathioprine, mycophenolate...